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On behalf of the Scientific Committee, I am very pleased to welcome the 
participants of the 3rd Symposium of Young Researchers on Pharmaceutical 
Technology, Biotechnology and Regulatory Science. Special greetings to the young 
researchers who report on their PhD work at this event. 
The symposium series launched before last year was a new initiative of the 
Institute of Pharmaceutical Technology and Regulatory Affairs, University of 
Szeged. The aim of this program was to get to know the work of Hungarian and 
foreign PhD students working at the institute, to master the basic rules of 
presentation and discussion. Early acquisition of this knowledge/skills is extremely important for 
mobility programs, conferences, publications and later for defense of theses.  
The successful 1st Symposium gave us the idea to invite our cooperative partners to participate in the 
2nd Symposium. We were delighted to welcome 16 PhD students from Serbia, Romania, Czech 
Republic, Bosnia-Herzegovina and Slovenia. 70 colleagues were participated at this symposium and the 
program included 1 plenary lecture and 39 oral presentations. Since we are past two successful 
symposia, we decided to continue this series. 
The current 3rd Symposium was announced as an online symposium in view of the COVID-19 pandemic. 
We are very pleased that a large number of participants have registered for this event and 53 PhD 
students and young researchers from 11 countries (Bosnia and Herzegovina, Bulgaria, Czech Republic, 
Estonia, Germany, Hungary, Italy, Romania, Serbia, Slovenia, Spain) submit lectures. This is a three-day 
event provides a good opportunity to discuss the new developments and the future directions of the 
pharmaceutical sciences. 
I am looking forward to having a successful conference with fruitful discussions.  
 
Prof. emer. Piroska Szabó-Révész 
Head of Scientific Committee 
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Wednesday, 20th January – 9:00-16:15 CET 
 
  9:00 - 10:15 Opening Ceremony and Plenary Session 
10:15 - 11:00 Session 1 
11:00 - 11:20  Break 
11:20 - 12:35 Session 2 
12:35 - 13:30 Lunch break 
13:30 - 14:45 Session 3 
14:45 - 15:00 Break 
15:00 - 16:15 Session 4 
19:00 -   Networking event 
 
 
Thursday, 21st January – 9:30-15:45 CET 
 
  9:30 - 10:45 Session 5 
10:45 - 11:00 Break 
11:00 - 12:15  Session 6 
12:15 - 13:00 Lunch break 
13:00 - 14:15 Session 7 
14:15 - 14:30 Break 
14:30 - 15:45 Session 8 
19:00 -   Game Night 
 
 
Friday, 22nd January – 9:30-14:30 CET 
 
  9:30 - 10:45 Session 9 
10:45 - 11:00 Break 
11:00 - 12:15  Session 10 
12:15 - 13:00 Lunch break 
13:00 - 14:15 Session 11 
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Wednesday, 20th January – 9:00-16:15 CET 
9:00-9:15 Opening Ceremony 
9:15-10:15 Plenary Session: Prof. Dr. Csaba Szántay (Gedeon Richter Plc.) 
    The hidden role of the human factor in scientific thinking 
10:15-11:00 Session 1 – Chairs: Dr. Barbora Vranikova, Dr. Noemi Csaba 
OP-1 – 10:15-10:30  Ruba Ismail, Ildikó Csóka 
 What are the regulatory aspects surrounding nanopharmaceuticals 
development? 
OP-2 – 10:30-10:45  Andrea-Gabriela Crișan, Sonia Iurian, Cătălina Bogdan, Lucia Rus, Alina 
Porfire, Sebastian Porav, Kinga Ilyés, Ioan Tomuță 
Personalized Fused Deposition Modeling 3D printed (FDM-3DP) tablets: a 
Quality by Design (QbD) approach 
OP-3 – 10:45-11:00  Tamás Kiss, Gábor Katona, Rita Ambrus 
Modifying the release of an antiparkinsonian drug by using mesoporous 
carrier 
11:00-10:20 Break 
11:20-12:35 Session 2 – Chair: Dr. Alina Porfire, Dr. Szilvia Berkó 
OP-4 – 11:20-11:35  Mahwish Mukhtar, Rita Ambrus 
Spray dried hyaluronic acid nanoplexes conjugated with chitosan and its 
derivatives for the pulmonary administration as dry powder inhalers for 
tuberculosis 
OP-5 – 11:35-11:50  Merima Sirbubalo, Amina Tucak, Edina Vranić 
Additive manufacturing of PLA microneedles for transdermal durg 
delivery 
OP-6 – 11:50-12:05  Zorana Mutavski, Senka Vidović 
Potential of vinegar as extraction solvent: can we use it for herbal 
preparation? 
OP-7 – 12:05-12:20  Črt Dragar, Tanja Potrč, Sebastjan Nemec, Robert Roškar, Stane Pajk, 
Slavko Kralj, Mirjana Gašperlin, Petra Kocbek 
 Development of magnetic nanoparticles for targeted drug delivery 
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OP-8 – 12:20-12:35  Reihaneh Manteghi, Katalin Kristó, Gerda Szakonyi, Ildikó Csóka 
 Strategies for development of antimicrobial peptides and proteins  
12:35-13:30 Lunch break 
13:30-14:45 Session 3 – Chair: Dr. Senka Vidović, Dr. Géza Regdon jr. 
OP-9 – 13:30-13:45  Hussein Akel, Ruba Ismail, Gábor Katona, Ildikó Csóka 
Lipid-based nanosystems for the nose-to-brain delivery of biological drug, 
Insulin 
OP-10 – 13:45-14:00  Zsófia Németh, Dorina Gabriella Dobó, Edina Pallagi, Ildikó Csóka 
Quality-focused formulation - QbD-based liposome design and 
development 
OP-11 – 14:00-14:15  Stanislava Simeonova, Tsenka Grancharova, Plamen Zagorchev, Bissera 
Pilicheva 
Near-infrared light-responsive magnetic nanoparticles - preparation and 
application in photothermal therapy 
OP-12 – 14:15-14:30  Erna Turković, Jelena Parojčić 
Application of artificial neural network in understanding critical material 
properties governing orodispersible film disintegration 
OP-13 – 14:30-14:45  Kairi Tiirik, Liis Preem, Kadi Sagor, Marta Putrinš, Tanel Tenson, Karin 
Kogermann 
In vitro and ex vivo models for assessing the antibiofilm properties of 
wound dressings 
14:45-15:00 Break 
15:00-16:15 Session 4 – Chair: Dr. Wehad Ibrahim, Dr. Gábor Katona 
OP-14 – 15:00-15:15  Davide D’Angelo, Francesca Buttini, Fabio Sonvico 
 Inhalable cyclosporine powder for immunosuppressive treatment 
OP-15 – 15:15-15:30  Eszter L. Kiss, Mária Budai-Szűcs, Erzsébet Csányi 
 Mucoadhesive nanostructured lipid carriers for ophthalmic use 
OP-16 – 15:30-15:45  Gabriela Nistor, Marius Mioc, Roxana Ghiulai, Roxana Racoviceanu, 
Codruta Soica 
Synthesis of betulinic acid 1,2,4-triazole derivatives suitable for 
cyclodextrin inclusion complex formulation 
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OP-17 – 15:45-16:00  Edit Benke, Christina Winter, Piroska Szabó-Révész, Eva Roblegg, Rita 
Ambrus 
Effect of solvent compositions on habits and in vitro aerodynamic results 
of spray-dried pulmonary formulations 
 
OP-18 – 16:00-16:15  Krisztián Pamlényi, Katalin Kristó, Orsolya Jójárt-Laczkovich, Géza 
Regdon jr. 
Preparation and investigation of permeability and physical-chemical 
properties of buccal films with sodium alginate 







Thursday, 21st January – 9:30-15:45 CET 
9:30-10:45 Session 5 – Chair: Dr. Francesca Buttini, Dr. Rita Ambrus 
OP-19 – 9:30-9:45  S. P. Yamini Kanti, Ildikó Csóka, Orsolya Jójárt-Laczkovich, Livia Adalbert 
Analysis of the regulations for medical devices in Europe & future 
perspectives 
OP-20 – 9:45-10:00  Tsenka Grancharova, Stanislava Simeonova, Bissera Pilicheva, Plamen 
Zagorchev 
Synergistic effect of magnetic nanoparticles and chemotherapeutic drugs 
in cancer 
OP-21 – 10:00-10:15  Balázs Attila Kondoros, Zoltán Aigner 
Evaluation of fenofibrate-cyclodextrin complexes prepared by co-grinding 
method 
OP-22 – 10:15-10:30  Kaisa Põhako, Karin Kogermann, Tanel Tenson, Külli Kingo 
Towards understanding the safety and biocompatibility of electrospun 
fibers 
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OP-23 – 10:30-10:45  Amina Tucak, Merima Sirbubalo, Edina Vranić, Andreas Zimmer 
 Solid lipid nanoparticles as drug delivery systems for MicroRNA 
10:45-11:00 Break 
11:00-12:15 Session 6 – Chair: Prof. Dr. Edina Vranić, Dr. Tamás Sovány 
OP-24 – 11:00-11:15  Lucia Ruxandra Tefas, Cătălina Bogdan, Alina Porfire, Tryfon Digkas, 
Thomas De Beer, Ioan Tomuță 
Development of liposomal drug delivery system as a strategy for 
improving bioavailability and therapeutic efficacy, by Design of 
Experiments. A case study. 
OP-25 – 11:15-11:30  Luca Éva Uhljar, Sheng Yuan Kan, Norbert Radacsi, Rita Ambrus 
 Preformulation studies of ciprofloxacin loaded PVP nanofibers 
OP-26 – 11:30-11:45  Nikolay Zahariev, Bissera Pilicheva 
Application of 32 experimental design in the preparation of casein 
nanoparticles as potential drug carriers 
OP-27 – 11:45-12:00  Ana Milanović, Sandra Cvijić 
Paediatric PBPK modeling: Prediction of drug exposure following oral 
dosing of different paracetamol formulations in fasted and fed states 
OP-28 – 12:00-12:15  Stella Zsikó, Erzsébet Csányi, Szilvia Berkó 
 New perspectives of skin penetration testing methods 
12:15-13:00 Lunch break 
13:00-14:15 Session 7 – Chair: Dr. Bissera Pilicheva, Dr. Katalin Kristó 
OP-29 – 13:00-13:15  Ernő Máté Benkő, Ilija German-Ilič, Géza Regdon Jr., Ildikó Csóka, Klára 
Pintye-Hódi, Stane Srčič, Tamás Sovány 
 Investigation of drug-matrix interaction in directly compressed matrices 
OP-30 – 13:15-13:30  Roxana Ghiulai, Marius Mioc, Gabriela Nistor, Roxana Racoviceanu, 
Codruta Soica 
Design and synthesis of betulinic acid gold nano-particles with enhanced 
pharmaceutical properties 
OP-31 – 13:30-13:45  Chiazor Ogadah, Šklubalová Zdeñka, Vraníková Barbora 
Biorelevant dissolution testing of matrix systems based on combination 
of mucoadhesive polymers 
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OP-32 – 13:45-14:00  Nikolett Kis, Szilvia Berkó, Erzsébet Csányi 
Investigation of dermal semisolid in situ film-forming systems containing 
lidocaine hydrochloride with QbD approach 
OP-33 – 14:00-14:15  Laura Falkenstein, Joerg Breitkreutz, Peter Kleinebudde 
Deposition studies on a systematically modified paediatric throat 
geometry 
14:15-14:30 Break 
14:30-15:45 Session 8 – Chair: Dr. Raphael Wiedey, Dr. Livia Adalbert 
OP-34 – 14:30-14:45  Mercedes Vitek, Mirjam Gosenca Matjaž, Mirjana Gašperlin, Robert 
Roškar, Alenka Zvonar Pobirk 
Antioxidant efficacy of vitamins loaded lipid-based delivery systems with 
different microstructure for dermal application 
OP-35 – 14:45-15:00  Fanni Falusi, Anita Kovács, Erzsébet Csányi 
 Investigation of foams for topical use 
OP-36 – 15:00-15:15  Yousif H-E. Y. Ibrahim, Katalin Kristó, Géza Regdon jr., Tamás Sovány 
Development and optimization of the coating processes of lysozyme 
loaded pellets for oral delivery 
OP-37 – 15:15-15:30  Nguyen Viet Khan, Ivo Laidmäe, Karin Kogermann, Andres Meos, Duc Viet 
Ho, Ain Raal, Hoai Thi Nguyen, Jyrki Heinämäki 
Electrospun amphiphilic nanofibers for stigmasterol-loaded delivery 
systems 
OP-38 – 15:30-15:45 Fakhara Sabir, Gábor Katona, Ruba Ismail, Ildikó Csóka 
Nose to brain delivery of n-propylgallte loaded lipid nanoparticles for 
targeting glioblastoma multiforme via QbD approach 
19:00-  Game Night  
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Friday, 22nd January – 9:30-14:30 CET 
9:30-10:45 Session 9 – Chair: Dr. Jelena Djuriš, Dr. Erzsébet Csányi 
OP-39 – 9:30-9:45  Anže Zidar, Julijana Kristl 
 Challenges in nanofiber testing in vitro 
OP-40 – 9:45-10:00 Carla Garcia-Mazas, Marcos García Fuentes, Noemi Csaba 
 New polymeric nanocomplexes against glioblastoma initiating cells 
OP-41 – 10:00-10:15 Stefana Suciu, Sonia Iurian, Rita Ambrus, Catalina Bogdan, Ioan Tomuță 
Milk oral lyophilisates with loratadine: screening for new excipients for 
paediatric use 
OP-42 – 10:15-10:30 Bence Sipos, Gábor Katona, Ildikó Csóka 
Nose-to-brain applicability of Meloxicam-loaded Soluplus polymeric 
micelles 
OP-43 – 10:30-10:45 Alharith A. A. Hassan, Katalin Kristó, Tamás Sovány 
 Printing of peptide-loaded hybrid nanoparticles for oral delivery 
10:45-11:00 Break 
11:00-12:15 Session 10 – Chair: Prof. Dr. Codruta Soica, Dr. Urve Paaver 
OP-44 – 11:00-11:15 Marija Djuranović, Svetlana Ibrić 
Application of deep learning tools in prediction of printability of 3D 
printed tablets 
OP-45 – 11:15-11:30 Martin Cseh, Zsolt Geretovszky, Zoltán Veréb, Ferenc Bari 
The 3D Printing Center of the University of Szeged: opportunities and 
challenges 
OP-46 – 11:30-11:45 Petra Party, Rita Ambrus 
Preparation and characterization of carrier-free dry powder inhalers 
containing nanosized active ingredient 
OP-47 – 11:45-12:00 Sandra Robla, Jose Manuel Ageitos, Rubén Varela Calviño, Sulay Tovar, 
Noemi Csaba 
 Bioinspired pollen microcapsules to overcome mucosal barriers 
OP-48 – 12:00-12:15 Siniša Simić, Jelena Vladić 
Overview: Supercritical carbon dioxide versus subcritical water extraction 
of bioactive compounds from herbal material 
12:15-13:00 Lunch break 
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13:00-14:15 Session 11 – Chair: Prof. Dr. Mirjana Gašperlin, Dr. Mária Budai-Szűcs 
OP-49 – 13:00-13:15 Patrícia Varga, Rita Ambrus, Csilla Bartos 
Development of spray-dried meloxicam-containing microcomposites 
using biocompatible matrix 
OP-50 – 13:15-13:30 Marius Mioc, Roxana Ghiulai, Gabriela Nistor, Roxana Racoviceanu, 
Codruta Soica 
Structural design of triterpenic acid 1,2,4-triazole linked gold nanoparticle 
bioconjugates, as potential treatment for malignant melanoma 
OP-51– 13:30-13:45 Sebastian Pohl, Peter Kleinebudde 
Transfer of twin-screw granulation process using a shear stress 
description of screw configuration 
OP-52 – 13:45-14:00 Sheila Barrios Esteban, Sonia Reimondez-Troitiño, Ruman Rahman, 
Cameron Alexander, Marcos Garcia-Fuentes, Noemi Csaba 
Protamine-based nanoparticles: an attractive gene delivery system for 2D 
and 3D glioblastoma models 
OP-53 – 14:00-14:15 Yasmin Ranjous, Dóra Kósa, Zoltán Ujhelyi, Géza Regdon jr., Krisztina 
Anita Nagy, Zoltán Kónya, Ildikó Bácskay, Tamás Sovány 
Optimization of the functionalization method of titanate nanotubes in 
order to use them as drug delivery systems 
14:15-14:30 Closing Ceremony 
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What are the regulatory aspects surrounding 
nanopharmaceuticals development? 
Ruba Ismail1,2, Ildikó Csóka1,2 
1Institute of Pharmaceutical Technology and Regulatory, Faculty of Pharmacy, 
University of Szeged, Szeged, Hungary 
2Department of Applied and Environmental Chemistry, Institute of Chemistry, Faculty 
of Science and Informatics, University of Szeged, Szeged, Hungary 
 
Tremendous effort has been devoted over the last two decades for developing nanomedicine-
based products particularly in the field of drug delivery systems. Nanopharmaceuticals, due 
to their special their physiochemical characteristics and behaviour, have proved to hold 
fantastic potential for addressing the questions of unmet clinical needs. But still and all, 
nanopharmaceuticals R&D needs a complex and comprehensive global critical thinking not to 
mention that there are still many challenges in their regulations. Hence, this presentation aims 
at providing an overview on the regulatory needs and risks of nanopharmaceuticals with a 
focus on the Food and Drug Administration (FDA) and European Medicine Agency (EMA) 
regulations. Towards boosting the translation of nanopharmaceuticals to clinical applications, 
Quality by Design (QbD), as a risk-based methodology, is greatly recommended to be followed. 
In addition to considering the risk assessment focused design, the whole research needs to be 
performed with great attention to its complexity and multidisciplinary character. 
 
Acknowledgements: This work was supported by the Ministry of Human Capacities, Hungary 
(Grant TKP-2020) and Gedeon Richter Ltd – GINOP project (2.2.1-15-2016-00007). 
 
References  
1 Ismail R.  PhD Thesis, University of Szeged (2020).  
2 Ismail R.; Sovány T.; Gácsi A.; et al. Pharm. Res. 36, 16 (2019). 
3 Pallagi I.; Ismail R.; Paál T.L.; Csóka I.  Eur. J. Pharm. Sci. 122, 160-169 (2018).  
4 Csóka I.; Pallagi E.; Paál T.L. Drug Discov. Today. 23,1340-1343 (2018). 
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Personalized Fused Deposition Modeling 3D printed 
(FDM-3DP) tablets: a Quality by Design (QbD) approach 
Andrea-Gabriela Crișan1*, Sonia Iurian1, Cătălina Bogdan2, 
Lucia Rus3, Alina Porfire1, Sebastian Porav4, Kinga Ilyés1, Ioan 
Tomuță1* 
1. Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and 
Pharmacy „Iuliu Hațieganu”, Cluj-Napoca, Romania 
2. Department of Dermopharmacy and Cosmetics, Faculty of Pharmacy, University of Medicine and Pharmacy 
“Iuliu Hațieganu”, Cluj-Napoca, Romania 
3. Department of Drug Analysis, Faculty of Pharmacy, University of Medicine and Pharmacy „Iuliu Hațieganu”, 
Cluj-Napoca, Romania 
4. National Institute for Research and Development of Isotopic and Molecular Technologies, Cluj-Napoca, 
Romania 
 
Pharmaceutical manufacturing by three-dimensional printing (3DP) provides unique advantages, 
including individualization potential by associating customizable doses of various active 
pharmaceutical ingredients (APIs) with different release profiles in one drug delivery system (DDS). 
One of the most promising techniques is fused deposition modeling (FDM). The aim of this research 
was to explore FDM-3DP for the development of personalized immediate release (IR) DDSs with 
diclofenac sodium (DS) by applying the quality-by-design (QbD) approach. 
High drug loaded (50%) FDM 3D printable filaments were prepared by hot melt extrusion. Regarding 
the printing process, a systematic assessment of the influence of the selected independent variables 
(design feature, dosage form size and printing resolution) on the quality attributes of the 3D printed 
DDSs was conducted. By adjusting the dimensions of the digital models, tablets with API content in the 
range of 32-75 mg were produced. The optimum formulation represented by a concentric ring design 
tablet with a DS content of 50 mg presented 78% drug release after 5 minutes and 90% drug release 
after 10 minutes. A correlation between the investigated factors and the dissolution performance of 
the dosage forms was found as high-resolution printing (0.1 mm) and greater tablet dimensions 
promoted faster release of the API. 
In conclusion, by employing the QbD approach to investigate the influence of the printing parameters 
and the dimensions of the DDS on the dissolution performance and API content of the dosage forms, 
preparation of tablets with very rapid dissolution and adjustable doses of API was completed. 
 
Acknowledgements: This project was supported by “Iuliu Hațieganu” University of Medicine and 
Pharmacy internal doctoral research grant 1680/34/19.01.2018 and by The European Social Found, 
Human Capital Operational Programme 2014-2020, project no. POCU/380/6/13/125171. 
 
Supervisor: Prof. Ioan Tomuță 
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Modifying the release of an antiparkinsonian drug by using 
mesoporous carrier 
Tamás Kiss, Gábor Katona, Rita Ambrus 
Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, 
University of Szeged, Szeged, Hungary 
 
The mesoporous silica-based materials are utilized in different field of pharmaceutical 
technology. One of the remarkable applications is based on the incorporation of active 
pharmaceutical ingredients (APIs) molecules into the mesopores. If the drug release rate is 
limited, it can be accelerated after loading drug into the mesoporous silica thanks to its 
stabilized amorphous state, the increased contact surface and the improved aqueous wetting 
ability of the excipient. The deceleration of a highly soluble API dissolution by mesoporous 
silica is a less investigated area. 
Our aim was to explore the possibilities of per os administered drug release regulation by 
using hydrophobized mesoporous silica. The highly soluble model API was the levodopa 
methyl ester hydrochloride (LDME) which was loaded into the pores of SYLOID 3050 XDP and 
its sylilated derivatives. The sylilation was executed with trimethylchlorosilane (TMCS). The 
reaction resulted in products with lower aqueous wetting ability. The hydrophobization 
reaction was reproducible after standardizing the adsorbed water content of silica, the 
occurence of the process was proven with FT-IR, charge titration and contact angle 
measurements. 
The LDME was loaded into the pores of silica with different hydrophobization extent in the 
range of 5-20 w/w% API. The drug was stable amorphous during the 1-month investigation 
period at 40 °C and 70% relative humidity (ICH Q1A (R2) guideline). The API was homogenously 
distributed in the products. The drug release could be regulated by controlling the wetting 
ability of silica. The hydrophobization extent effect was more remarkable when the loading 
degree was lower. 
 
Acknowledgement: Ministry of Human Capacities, Hungary grant, TKP-2020 
 




III. Symposium of Young Researchers on Pharmaceutical 
Technology, Biotechnology and Regulatory Science 






Spray dried hyaluronic acid nanoplexes conjugated with 
chitosan and its derivatives for the pulmonary 
administration as dry powder inhalers for tuberculosis 
Mahwash Mukhtar, Rita Ambrus 
Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, 
University of Szeged, Szeged, Hungary 
 
The current therapies fail to deliver the drug to the alveolar macrophages in lungs, where 
causative agent resides, for the treatement of tuberculosis [1]. Hence, the ineffective drug 
delivery approaches lead to the drug toxicity and organ damage. Dry powder inahlers (DPIs) 
have recently shown promising results for the site specific drug delivery in the infectious 
diseases. Therefore, we developed nanoplexes based DPIs comprised of biocompatible 
polymer hyaluronic acid (HA) complexed with chitosan (CS), thiolated chitosan (TC) and 
mannsosylated chitosan (MC) individually to explore their affinity for alveolar macrophages to 
achieve higher drug deposition in deeper tissues of lungs. Nanoparticles were prepared by 
ionic gelation method [2] and later optimized by Design of Experiment (DoE), Box-Behnken 
design, prior to spray-drying to obtain nano-DPIs encapsulated with isoniazid. The size, 
morphology, physico-chemical properties, in-vitro release profile, in-vitro permeation, 
aerodynamic profile and in-silico drug deposition of the nano-powders were promising. 
Furthermore, biocompatibility assay revealed the safety profile of nanoplexes. Moreover, 
spray drying enhanced the rheological properties of nano-powders. Altogether, DPIs 
highlighted promising results based on the preliminary fundamental outcomes with enhanced 
drug encapsulation efficiency and drug deposition profile. 
 
Acknowledgements: This work was supported by the GINOP-2.3.2-15-2016-00036 
('Development and application of multimodal optical nanoscopy methods in life and materials 
sciences'), and Ministry of Human Capacities, Hungary grant TKP-2020. 
 
References  
1 Mukhtar, M. et al. Expert Opin. Drug Deliv, 17(9), 1239-1257 (2020). 
2 Mukhtar, M. et al. Int. J. Biol. Macromol. 165, 3007-3019 (2020) 
 
Supervisor: Rita Ambrus 
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Additive manufacturing of PLA microneedles for 
transdermal drug delivery  
Merima Sirbubalo, Amina Tucak, Edina Vranić 
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
Sarajevo, Sarajevo, Bosnia and Herzegovina 
 
As physical permeation enhancers, microneedles (MNs) can modificate stratum corneum by 
creating microchannels, that are large enough to enable drugs, including macromolecules, to 
enter the skin while being small enough to avoid pain, irritation, and needle phobia [1,2]. 
Great emphasis is placed on the production process of microneedles itself, the selection of 
the most suitable materials as well as their shape, density, and size. This work aimed to 
fabricate biodegradable PLA MNs using additive manufacturing, more precisely fused 
deposition modeling (FDM) technology, and investigate the effect of varying geometry and 
print settings on the printed MNs in order to develop microneedles of optimal shape, density, 
and height. 
Ultimaker 5S 3D printer (Ultimaker, Netherlands) was used to print triangular and cylindrical 
MNs with different heights (0,6 mm, 1,2 mm, and 1,8 mm) and different number and 
orientation of single arrays on the base (5x5, 3x3, 1x5) using 2.85 mm PLA filament (3D 
Republika, Serbia). The results showed the ability of Ultimaker 5S to successfully print MNs 
with different shapes, where the triangular shape was chosen to be more acceptable for 
transdermal delivery. 1.8 mm height was chosen as the optimal height for the MNs, while the 
5 x 5 orientation of single arrays on the base resulted in more accurately printed MNs without 
a lot of waste material between the needles. Based on the results obtained, it can be 
concluded that FDM printing parameters can easily be adjusted to develop MNs of optimal 
shape, density, and height for transdermal drug delivery.  
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Apple cider vinegar (ACV) is widely used around the world as a flavoring and as a food 
preservative. Also, its use has been proposed in folk medicine as a health benefit for obesity 
and overweight, arthritis, asthma, cough, diarrhea, eczema, diabetes, and high cholesterol, 
and other disorders and diseases. It is produced by alcoholic and acetic fermentation (double 
fermentation). The ACV chemical composition is affected by the chemical composition of the 
apples used as a raw material, and by the applied fermentation process. According to the 
available data, ACV contains various organic acids-dominantly acetic acid, phenolic 
compounds, minerals (like potassium, sodium, calcium, and iron), vitamins (C and B group), 
and pectin.  
In this study, ACV was used as an extraction solvent for the extraction of phenolic compounds 
from the black elderberry fruit. Conventional modified maceration and ultrasound-assisted 
extraction were used as the extraction techniques. The potential of several different ACVs as 
the extraction solvents was investigated. For the obtained ACV elderberryextracts, the 
analysis of phenolic compounds (TP), flavonoids, and anthocyanins were performed. Also, the 
effect of applied extraction process on the changes in pH and changes in sensory properties 
of obtained extracts was assessed. It has been observed that the ability to use ACV as an 
extraction solvent predominantly depends on the ACV production process, its chemical 
composition and microbiological status. The type of ACV production process affected the 
value of ACV pH, total solids, sugar content, acetic acid content, initial TP content, and sensory 
properties, which further affects the efficiency of extraction of phenolic compounds from 
black elderberry fruit, microbiological status and sensory properties of obtained extracts. 
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Among several types of nanoparticles, iron-oxide-based magnetic nanoparticles (MNPs) have 
shown great potential for their use as targeted drug delivery systems [1]. Despite numerous 
advantages, some limitations of MNPs need to be overcome before their application in clinical 
practice, including ineffective spatial guidance, poor colloidal stability, usually low drug 
loading, and inadequate drug release [1,2]. 
The aim of our work was to prepare MNPs based on the controlled assembly of 
superparamagnetic iron oxide (γ-Fe2O3) nanocrystals.  Thus, we had developed a one-pot 
method for the preparation of MNPs composed of several nanocrystals, tetradecan-1-ol, 
model drug, and surfactant (Brij®L4 or our own surfactant N1,N1-dimethyl-N2-(tricosan-12-
yl)ethane-1,2-diamine (SP11)). The method is based on hot homogenization of the 
hydrophobic phase containing a nonpolar surfactant into the aqueous phase, using 
ultrasonication. The resulting MNPs showed good colloidal stability and relatively high drug 
loading capacity (up to 7.6 wt. %). The surfactant selection influenced the MNPs morphology, 
drug release profile, and MNPs surface charge, whereas the MNP size, iron oxide content, and 
drug loading were comparable among investigated formulations. 
To sum up, the specific composition gives these MNPs promising characteristics for application 
in nuclear magnetic resonance imaging and magneto-thermally-triggered targeted drug 
delivery [3,4]. They are therefore attractive candidates as novel nanotheranostics. 
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Due to the several unresolved challenges of antimicrobial peptide and protein agents 
including low bioavailability, high manufacturing cost and toxicity concerning their delivery to 
the target site, their potential has yet to be concerned [1]. 
Novel chemical modification approaches and novel formulations within the limits of 
nanotechnology offer several opportunities to overcome these barriers. However, these 
approaches hide several risks. To avoid these risks and control the quality of the final product, 
this study presents a Quality by Design (QbD) based peptide and protein modification and 
formulation design.  
Evaluation of the potential risks in the peptide PEGylation process through the example of 
PGLa as well as, the effective delivery of proteins with antimicrobial activity was accomplished 
through the example of lysozyme in a novel formulation strategy as layer-by-layer 
polyelectrolyte core-shell nanoparticle [2]. The precipitation method was applied for the 
formulation of core and the second step was the layering of polymers according to the 
factorial design. The samples were lyophilized and then analytical investigations were 
performed such as e.g. measurement of FTIR and zeta potential. The particle size, 
encapsulation efficiency, content of -helix structure and enzyme activity were the 
optimization parameters. 
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Lipid-based nanosystems with the aim of direct nose-to-brain delivery of therapeutics are of 
great interest nowadays for both biomolecules and abiotic molecules. The hormone insulin, 
administered nasally, could be promising for Alzheimer's disease therapy, which only has 
fruitless treatments that interfere with its progression. Insulin may play this role by either 
being involved in the clearance of beta-amyloid from the brain or increasing memory 
performance. Since insulin is a macromolecule polypeptide with a delicate and hydrophilic 
nature, its delivery to the brain is limited by the lipophilic blood-brain barrier (BBB) not to 
mention the low stability issue. Encapsulation of insulin in solid lipid nanoparticles (SLNs) holds 
great potential in boosting insulin ability to reach the brain, owing to their nanosize, 
biocompatibility, and lipophilicity. Further coating of SLNs with a mucoadhesive polymer, 
chitosan, can improve the drug release profile, mucoadhesion to the olfactory region and 
permeation through the nasal mucosa, which are the three key steps for any nasally applied 
drug to be delivered to the brain. 
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Formulations should carry the quality designed into the products to meet the pharmaceutical 
requirements. The Quality by Design (QbD) approach ensures the quality of medicines by developing 
and manufacturing products following statistics-, analytics- and risk-management-based 
methodologies [1]. 
This research aims to systematise the characteristics of the components (material attributes, MAs) and 
the preparation settings (process parameters, PPs) in case of the thin-film hydration liposome 
preparation technique. Furthermore, the study specifies the quality target product profile of a 
liposomal formulation and the critical quality attributes of the liposomes. Also, it identifies those MAs 
and PPs that influence the characteristics of the vesicles [2]. 
The theory was supported with practical research; the effect of the working temperature, the 
phosphatidylcholine-cholesterol ratios, the PEGylated phospholipid concentration, the type of the 
hydration media and the cryoprotectants were studied in different formulations. The results present 
the key points of a Risk Assessment (RA)-based experimental design, and the impacts of the critical 
factors mentioned above based on the investigation of the liposomal characteristics (size, surface 
charge, thermodynamic behaviours and structural investigations). 
The study revealed the relevance of the QbD-based RA in the thin-film hydration-based liposome 
preparation process and shown the main effects of the tested critical factors. The results ensure that 
the understanding and the application of the QbD elements in the pharmaceutical developments help 
to influence and to reach the aimed quality of the formulated product. 
 
Acknowledgements: This work was supported by the Gedeon Richter’s Talentum Foundation; the 
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One of the non-invasive techniques used in the fight against cancer is conventional 
hyperthermia, which, despite being very effective in destroying tumor cells, has low spatial 
selectivity and severely affects healthy tissues. Photothermal therapy (PTT), which uses near-
infrared absorbing magnetic nanoparticles to generate heat from optical energy, is of great 
interest as the method is controllable, highly efficient, less invasive and poses much fewer side 
effects compared with standard approaches such as chemotherapy and radiotherapy. The 
combination of photothermal therapy with hyperthermia mediated by magnetic 
nanocomposites can also help in eliminating inflammatory macrophages and enhancing 
tumor-cell permeability and retention effect.  
Over the last decade, scientists worldwide have focused on improving the PTT effects of 
magnetic nanoagents by optimizing synthesis and coating methods with appropriate near-
infrared (NIR) -sensitive materials. In order to develop an effective PTT mediator, the carriers 
created must meet the following criteria: small size, photostability, facile synthesis, non-
toxicity and dual modality. The magnetic materials irradiated under a NIR laser must make full 
usage of the resulting thermal energy to destroy cancer cells without affecting healthy tissues. 
An optimal combination of materials, synthesis methods, and coating approaches are 
presented in this study focusing on Fe3O4 magnetic nanoparticles. In addition, the possibilities 
for optimizing the effects of magnetic hyperthermia are considered. 
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Orodispersible films (ODF) are thin strips that are intended to disintegrate within seconds 
upon contact with liquid. Critical material properties (CMP) affect ODF disintegration, but due 
to complexity of data, film performance is difficult to predict. The aim of this work was to 
develop artificial neural network (ANN) model as tool for prediction of ODF performance 
based on its CMP.  
Dataset values for building ANN model were based on the in-house experimental results and 
included following input parameters: concentration of active ingredient, its solubility, 
molecular weight and polymer ratio, ratio of superdisintegrants, plasticizers, film surface-area, 
weight, thickness, mechanical properties (Young’s modulus, tensile strength, % elongation 
and complex modulus) and disintegration time as output. Preprocessing operators were 
applied to filter examples, select attributes and set roles of attributes. Split validation is 
performed to estimate how accurately model performs on unseen data. Root-mean-square 
error (RMSE) is used to compare prediction errors of data. 
ANN model with one hidden layer showed accurate predictions, while higher number of layers 
led to overfitting therefore higher RMSE values for testing data. ODF mechanical properties 
as input are highly related with film disintegration as the selected performance indicator, 
accompanied with high predictability. ANN was able to perform prediction on ODF 
disintegration time with high accuracy characterized with RMSE 0.871 and 0.176 for training 
and testing set, respectively.  
The results obtained indicate that it is possible to build predictive ANN which could lead to 
better understanding of complex relationship between ODF properties and their effect on film 
disintegration. 
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properties of wound dressings 
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Insufficient infection treatment in chronic wounds is associated more and more with the 
presence of biofilm, thus, novel biofilm targeting wound care products are being developed. 
It is of importance to have appropriate analytical methods to quantitatively evaluate these 
wound care products for their anti-biofilm properties. The aim of present study was to develop 
in vitro and ex vivo biofilm models for assessing the antibiofilm properties of electrospun 
wound dressings.  
In vitro model was created using thermally crosslinked electrospun gelatine (GEL) matrix as an 
artificial skin and for ex vivo model pig ear skin was used. Different pathogenic bacteria, 
isolated from wounds, were used to develop a biofilm. The model was set up in 24-wellplates 
on top of GEL matrix or pig skin bacterial dispersion was added and after that chloramphenicol 
(CAM)-loaded electrospun wound dressings were applied. These systems were incubated for 
24 and 48 h, subsequently planktonic bacteria were removed, biofilm disrupted and 
quantified.  
The results show that GEL matrix is suitable to be use as an artificial skin in in vitro biofilm 
model, as bacteria adhered to its surface and formed a biofilm. Compared to GEL matrix, the 
ex vivo model on pig skin appeared to be a better and preferred surface for the biofilm 
formation. Application of CAM-loaded wound dressings effectively reduced the biofilm 
formation in both models. To conclude, designed in vitro and ex vivo models allow 
comparing and evaluating the antibiofilm properties of wound dressings. 
Acknowledgements: Estonian Research Council projects PRG726 and PRG335.  
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Our research brings to the development of a high respirable powder for inhalation of 
Cyclosporine A (CsA) with improved dissolution rate. This powder was produced by spray 
drying using a low amount of excipients. Different powders were produced starting from 
aqueous solutions containing 10-20 % (w/w) of mannitol; 0-5% (w/w) of glycine and 60-45% 
(v/v) of ethanol according to a design of experiment. The aerodynamic performance was 
analyzed throw fast screening impactor and next generation impactor using RS01 inhaler. The 
dissolution profile of CsA powders was evaluated with a vertical diffusion cell apparatus 
(RespiCellTM) across a polycarbonate membrane. Curves obtained from dissolutions were 
linearized by the Weibull distribution. 
Twelve powder were characterized and the best results in terms of dissolution profile and 
respirability were obtained using a 20 % of mannitol for powder construction. In this way, 59.7 
± 2.8 minutes were requested to dissolve 63.2% of CsA. This value was significantly lower 
compared to the one of CsA raw material (169,5 ± 29 min). The CsA-Mannitol spray dried 
powder was successfully emitted by the powder device (>87%) and the fine particle fraction 
was higher than 70%. 
In conclusion, the work leads to the production and characterization on an inhalation powder 
with the potential to be administered directly to the lung for the prevention of rejection 
following lung transplantation and the containment of the inflammatory process due to SARS-
CoV-2 infection. 
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Today, the development of an effective ophthalmic drug delivery system is a major challenge. 
The most commonly used ophthalmic preparations are eye drops, which have low 
bioavailability due to the complex structure and elimination mechanism of the eye [1]. 
Nanostructured lipid carrier (NLC) is second-generation solid lipid nanoparticles that contain 
a lipid matrix of mixed solid and liquid lipids. These systems are ideal for the incorporation of 
drugs with low water solubility, such as corticosteroids [2]. 
The aim of the study was to incorporate dexamethasone (DXM) into mucoadhesive polymer-
containing nano lipid carriers to increase drug bioavailability. A 23 factorial experimental 
design was used in which the three factors were polymer, DXM, and emulsifier concentrations. 
The particle size, Zeta potential, polydispersity index, and Span value of the samples were 
analyzed. The biocompatibility of the formulations was assessed by human corneal toxicity 
tests and immunoassay analysis. Potential increases in bioavailability were analyzed using 
mucoadhesivity study, in vitro drug diffusion, and various penetration tests such as corneal-
PAMPA model, human corneal cell penetration, and ex vivo porcine corneal penetration by 
Raman mapping. The results showed that DXM can be incorporated into stable mucoadhesive 
NLC systems that are non-toxic. Mucoadhesive NLCs can create a depot on the surface of the 
cornea that can predict better bioavailability. 
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Pentacyclic triterpenes are natural compounds with a large plethora of described 
pharmacotherapeutic effects. Betulinic acid (BA) stands as a widely studied compound of this 
class, exhibiting multiple therapeutic effects such as: antiinflammatory, antiviral and 
antiproliferative. The low bioavailability o BA represents a major drawback which represented 
a starting point of multiple research directions, having the sole purpose of increasing BA’s 
bioavailability. One direction employed by the literature in this regard represents the 
synthesis of cyclodextrin (CD) inclusion complexes (1). Knowing that BA is a large pentacyclic 
structure herein we propose the synthesis of a BA-1,2,4-triazole derivative that can be easily 
incorporated into CD and can exhibit an improved antiproliferative effect as compared to BA. 
The proposed derivatization requires obtaining a BA halogenated derivative by allylic 
bromuration (C-30), that ca be subsequently used as an alkylating agent against a 3-thiol-1,2,4-
triazole derivative. 30-bromo-BA was obtained according to previously reported methods 
using NBS (2). The obtained compound was purified by flash column chromatography. The BA 
derivative was later reacted to 5-(4-metoxifenil)-4H-1,2,4-triazol-3-thiol, in presence of EtOH 
and EtONa. The completion of the reaction was monitored by TLC. The obtained compound 
was purified by flash column chromatography. FT-IR and LC-MS analysis confirmed the 
formation of 30-[3-(4-metoxiphenyl)-1H-1,2,4-triazol-5-yl-sulfanyl]-betulinic acid. Docking 
studies of the BA derivative an BA using CD as targets revealed that indeed our obtained 
compound shows a theoretical stronger affinity towards CD as compared to BA. The obtained 
compound and its CD formulations will be subjected to further biological assessments. 
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In the case of carrier-free dry powder inhalation systems (DPIs), the formulations can be 
prepared by various technological methods to bring the particles of the samples in the 
internationally recommended range of 1-5 microns. In addition to traditional particle size 
reduction technologies (such as milling), appeared sample preparation procedures (spray-
drying, spray-freeze-drying, and supercritical-fluid technology) to ensure the aerodynamically 
favorable particle morphology. Among the latter production methods, spray drying is already 
widespread, as it compares its advantages and disadvantages and proves to be a very 
promising production solution. The choice of the solvents used in spray drying and their 
proportions are in many cases based solely on the solubility of the drug and applied excipients, 
but it may also be noteworthy that each solvent composition may affect the habit of DPI 
powders and thus in vitro aerodynamic results. Observations in this regard have been reported 
in a few studies in the international literature [1, 2]. The present work aims to investigate the 
different concentrations of a given organic solvent, how it affects the physical properties, and 
the in vitro aerodynamic results of the prepared DPI powders. Based on the results, it can be 
concluded that due to the changes in the micrometric properties of the samples, the in vitro 
aerodynamic results can be tripled. Thus, in the development of spray-dried DPI, the solvents 
used in the production and their mixtures are of paramount importance. 
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Nowadays the buccal administration of active ingredients is an innovative method. 
Mucoadhesive films represent one of these possibilities of drug administration. Mucoadhesive 
films can be used to introduce the API to the systemic circulation. By this way of drug 
administration, the API enters the circulation without degradation and avoids the first pass 
effect of the liver [1]. Besides, this drug delivery system can be applied in pediatrics and 
geriatrics. The bases of buccal mucoadhesive preparations are polymers which have 
mucoadhesive properties [2]. 
Our work was focused on preparing buccal mucoadhesive polymer films which were based on 
sodium alginate (SA) and contained cetirizine dihydrochloride (CTZ). Our main aim was the 
preparation and the physico-chemical investigation of the prepared mucoadhesive films. 
In our present work SA and HPMC were used as film forming agents. Glycerol was added as 
plasticizer to the films, and CTZ was the API. The polymer films were prepared with solvent 
casting method at room temperature. The mechanical and physical-chemical properties of the 
films were investigated with different methods, such as thickness, tensile strength and in vitro 
mucoadhesion of films. The chemical properties were examined by FT-IR and Raman 
spectroscopy. The dissolution and permeation of the API were also tested. The results showed 
that almost all film compositions have sufficient mechanical properties. The API can distribute 
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This presentation aims to provide a structural & functional understanding of regulations for medical 
devices in the European Union. Medical Devices (MD) in the European Union are regulated by the 
European Commission based on their proposal in order to ensure the safety and efficacy of Medical 
Device, thus facilitating patient’s access to device in the European market. 
MD s are any instruments, appliances, software, implant intended to be used for medical purposes 
alone or in combination for diagnosis, prevention, prediction, treatment, replacement, of any disease, 
injury or disability or physiological/pathological state. In-Vitro MD is reagents, calibrators, 
instruments, software or system used alone or in combination to examine specimens (e.g.: blood & 
tissue) to provide further information for physiological/pathological state, congenital impairments, to 
track treatment response and to monitor therapeutic measures. 
The New Medical Device Regulations (EU) 2017/745 (MDR) & In Vitro-Diagnostics Medical Device 
Regulations (EU) 2017/746 (IVDR) aims to give national regulators much more control & oversight of 
Medical device industry. Companies should proactively comply with these upcoming changes; if they 
do not then they could possibly result in losing their license to operate. Hence, it is very important to 
develop a new model for the industry to get them quick market access according to the new Medical 
Device rules.  
In clinical practice, incidents including the breast implant and the hip replacements crisis have made it 
necessary to improve the regulatory & compliance approaches for the industry and hence raising a 
question about the quality aspect of the MD. Such incidents along with the understanding and 
addressing the critical factors of the pharmaceutical industry, namely the expectation of the patients 
and the requirements of the current legislations will determine of the quality of the MD. 
Applying new approaches, by implementing the quality-by-design (QbD) could efficiently increase the 
quality of MD fitting in the ever-changing regulatory landscape. Tailoring the early development phases 
of MD by adding elements that are currently widely applied, but not yet included in the QbD model in 
a structured way would allow a more conscious development. In this way the continuous development 
& innovation of MD could be facilitated in the life cycle of the device. 
Acknowledgments: This work was supported by the Ministry of Human Capacities, Hungary 
(Grant TKP-2020) 
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Magnetic nanoparticles (MNPs) are a clinically available biomedical tool and have been 
approved to serve as magnetic resonance contrast agents. MNPs are of great interest in a wide 
range of applications due to their unique physical properties. High surface to volume ratio 
allows MNPs functionalization with different ligands and coatings for various biomedical 
applications. Due to their magnetic properties, MNPs can be used as magnetic-guided drug 
delivery carriers. Conventional chemotherapeutics suffer several drawbacks such as 
nonspecific targeting, toxicity to the healthy cells, reduced stability, and drug resistance by 
the cancer cells. To overcome these limitations, MNPs with attached specific ligands (markers 
or molecules with tumour binding capacity) are used for targeted delivery of chemotherapy 
drugs to the cancer cells keeping the healthy cells unaffected. Moreover, nanocarriers have 
the potential to overcome chemotherapy drug resistance by bypassing the ABC-transporter 
mediated drug efflux mechanisms. Another promising application of MNPs in cancer therapy 
is via magnetic hyperthermia. Tumour cells are known to be more sensitive to temperature 
increase than normal cells. When used in conjunction with chemotherapy, magnetic 
hyperthermia offers substantial synergistic effects. Recent publications in the field reveal that 
combined chemo-phototherapy based on NIR laser irradiation using MNPs results in lower 
tumour growth and cancer regression due to efficient drug penetration in the tumour tissue. 
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Cyclodextrins (CD-s), and CD derivatives are widely used for the improvement of the 
physicochemical properties of poorly water soluble active pharmaceutical ingredients (API-s). 
Several methods (e.g., co-precipitation, kneading) require organic solvents to prepare these 
complexes. Nevertheless, complexation can be achieved via mechanochemical activation by 
co-grinding method. Generally, complexation with amorphous CD-derivatives requires shorter 
grinding time and results stable amorphous products. 
Our aim was to prepare API-CD complexes by co-grinding and use analytical techniques to 
describe the complexation process as a function of grinding time. In this study heptakis(2,6-
di-O-methyl)-β-cyclodextrin (DIMEB), an amorphous CD-derivative was used as a 
complexation agent, and fenofibrate (FEN), a BCS II. API was chosen as a model drug. FEN-
DIMEB physical mixture was prepared in 1:1 molar ratio. Co-grinding was performed in a 
mortar for 60 minutes, and samples were taken at predetermined intervals. Original 
components and samples were characterized by DSC, XRPD, FTIR methods. Dissolution 
properties of API, physical mixture, kneaded product, and co-grinded samples were also 
investigated. 
DSC investigation showed that the endothermic peak indicating the melting point of the API 
decreased continuously with increasing co-grinding time. Meanwhile, a new, continuously 
growing exothermic peak appeared at a higher temperature after 30 minutes of grinding time. 
XRPD studies showed a linear trend of decreasing peaks with the increasing grinding time, 
after 60 minutes the product was totally amorphous. Based on FTIR results, presence of 
molecular interactions was detected between the host and gest molecules. The product 
obtained by co-grinding showed similar dissolution property compared to the kneaded 
product due to the presence of stable amorphous molecular complex. 
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Every year the number of patients with chronic wounds increases because of population aging 
and non-efficient wound treatment methods. Most chronic wounds are infected with bacterial 
biofilms. The presence of bacterial biofilms and the lack of good topical antimicrobial 
treatment options make the wound care even more difficult. Therefore, new strategies for 
wound management are needed. One wound dressing solution could be the antimicrobial 
electrospun nanofibers which enable to incorporate different drugs into their structure and 
deliver these successfully into the wound area. With this new potential treatment, it is 
important to test the safety and biocompatibility of these electrospun fibers before their 
administration to patients.  
The aim of this study was to test the safety and biocompatibility of electrospun fibrous 
matrices with and without antimicrobial agents on different eukaryotic cells. Three different 
eukaryotic cell lines were used (baby hamster kidney cells (BHK-21), human lung fibroblasts 
(MRC-5) and primary fibroblasts obtained from patients). The study had all relevant ethical 
committee permissions. Experiment setup was based on modified MTS assay that measures 
the cell viability. Morphology of fibers and biocompatibility were evaluated with scanning 
electron microscopy (SEM). The results showed that all tested electrospun fibers were safe 
and biocompatible. However, there were some differences in the viability of cells when 
pristine polymeric matrices and matrices with antimicrobial agents were compared. 
Furthermore, the behaviour of different cells varied. Further studies will test the cell 
migration, proliferation and differentiation on electrospun matrices in more depth in order to 
understand better the cell-fiber interactions.  
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MicroRNA-based medicines have drawn attention as a promising tool for the treatment of 
various diseases. Due to the poor biomembrane permeation, cellular uptake, and enzymatic 
instability of naked microRNA, the clinical success of gene therapy is mostly dependent on 
formulating efficient and safe transfection vectors [1]. Therefore, we aimed to develop 
cationic solid lipid nanoparticles (SLN) for gene therapy purposes.  
SLN containing 0.15% of stearylamine, 4.85% of Precirol ATO 5 (solid lipid), 1% of Tween 80, 
and 1% of Poloxamer 188, as non-ionic surfactants, were produced using a high-pressure 
homogenization process (800 bar and three cycles). microRNA 27-a was further complexed 
with SLN in the following SLN/microRNA ratios: 1:5, 1:2.5, 1:1, 2.5:1, 5:1, 10:1, 25:1 and 
characterized using dynamic light scattering, electrophoretic light scattering, and gel 
retardation assay. 
The SLN had a mean diameter of 112 ± 0.5 nm (PDI of 0.202 ± 0.011) and a zeta potential (ZP) 
value of +30.6 ± 1.25 mV. Complexation of SLNs with microRNA decreased a particle size from 
244.8 ± 2.7 to 120.4 ± 0.4 nm with an increasing weight ratio of SLNs, while the biggest particle 
size was observed in 1:1 ratio (1146 ± 110.2 nm) due to low ZP values (3.45 ± 0.2 mV). Further, 
ZP increased from -14.3 ± 0.4 mV to + 39.7 ± 0.5 mV. Both ELS data and gel retardation assay 
results revealed that complete complexation could be attained above the weight ratio of 5:1. 
Our investigations suggest that SLN poses a high potential to be non-viral gene carriers in 
miRNA replacement therapy. 
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There is mounting evidence for the anticancer effects of all-trans retinoic acid (ATRA) in different types 
of malignancies. However, ATRA treatment is usually associated with side effects, and most 
importantly with retinoid acute chemoresistance. Furthermore, ATRA shows reduced physicochemical 
stability, aqueous solubility and plasma half-life. Nanocarriers have emerged as promising strategies 
for delivering drugs to tumors. Therefore, this study aimed at developing an ATRA-based liposomal 
formulation with enhanced stability and therapeutic efficacy. 
ATRA-loaded liposomes (L-ATRA) were prepared by ethanol injection from egg phosphatidylcholine 
and cholesterol. Design of Experiments (DOE) was employed to study the influence of several 
formulation factors on the quality attributes of L-ATRA. 11 formulations were prepared according to a 
23 full factorial design, and characterized in terms of size, polydispersity, ATRA content and entrapment 
efficiency. An optimum liposomal formulation with desirable characteristics was evaluated in vitro 
regarding ATRA release. 
L-ATRA exhibited a mean size of 200-400 nm, and a narrow size distribution (polydispersity index < 
0.25). ATRA was successfully loaded into the liposomes with an efficiency of 70-80%. According to the 
DOE statistical analysis, L-ATRA attributes were mainly influenced by the concentrations of 
phospholipid and ATRA. The in vitro release study showed a maximum percentage of 72.5% ATRA 
released after 48h in a mixture of PBS pH 6.5 and ethanol 1:1 (v/v) at 37°C. 
Overall, this study reports the successful formulation and preparation of an ATRA-loaded liposomal 
formulation by DOE. L-ATRA could be a promising candidate for effective and safe delivery of ATRA in 
cancer patients. 
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Ciprofloxacin is a worldwide-used, broad-spectrum antibiotic with low water-solubility [1]. To 
earn higher solubility, and better bioavailability, nanofibers were fabricated as an amorphous 
solid dispersion with the polymer, polyvinylpyrrolidone (PVP). For the production, needle and 
needleless electrospinning methods were used [2]. The fiber size and morphology were 
observed by scanning electron microscopy (SEM). Physicochemical properties were 
characterized by X-ray powder diffraction (XRPD), differential scanning calorimeter (DSC), and 
Fourier-transform infrared spectroscopy (FTIR). The results proved the amorphous state of the 
CIP inside the nanofibrous mats. The solubility, in vitro dissolution rate, and in vitro diffusion 
were remarkably higher in the case of the nanofibers compared with the CIP powder or the 
physical mixture of the two components. The solubility of the CIP demonstrated a significant 
increase both in water (pH 6.3) and phosphate buffer solution (pH 7.4). In addition, fast-
dissolving formulations were developed, while 94±6% of the CIP was released in the first 5 
min. Moreover, in vitro diffusion from pH 6.8 to pH 7.4 also showed a notable increase. The 
stability of the nanofibrous samples was studied by SEM and in vitro dissolution. In conclusion, 
fast-dissolving formulations were built up which can be further investigated to develop 
appropriate pharmaceutical forms. 
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Production of nanoparticles by nano spray drying is strongly influenced by the process 
parameters - polymer concentration, solubilizing agent concentration, inlet temperature, 
pumping speed, spray rate, as well as the spray mesh size. 
The aim of the present study was to establish the optimal process parameters - polymer 
concentration and crosslinking agent concentration required to produce casein nanoparticles 
with optimal structural and morphological characteristics for use as drug carriers. 
A full 32 factorial design was used to study the influence of process parameters. Three different 
concentrations of casein solution were varied: low concentration 0.05%, medium 
concentration 0.1% and high concentration 0.15%. The influence of the crosslinking agent 
concentration (CaCl2, Mw = 110.98 g/mol) was also investigated: low concentration 0.5 M, 
medium concentration 1.0 M and high concentration 1.5 M. A spray membrane with a mesh 
size of 4.0 μm was used and the following spray conditions were applied: inlet temperature 
40 °C, solution feed rate 50%, spray intensity 70%, drying gas speed 120 L/min, pressure 30 
nbar. 
Using the nano spray drying method, nine models of nanoparticles were obtained, which were 
characterized based on shape, size and size distribution, surface morphology and yield. 
Optimal conditions to produce casein nanoparticles were derived and promising models were 
selected to be studied as potential drug-delivery systems. 
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In recent years, physiologically-based pharmacokinetic (PBPK) models have been increasingly 
used in paediatric drug development. Moreover, the value of such approach has been 
recognized by the regulatory authorities (1). 
The aim of this study was to evaluate paracetamol absorption and disposition in children 
following oral administration of sustained-release hot-melt coated (HMC) granules and tablets 
made of HMC granules (2,3) in comparison to immediate-release uncoated granules and 
tablets made of uncoated granules, using PBPK modelling. Paracetamol-specific PBPK model 
was firstly developed and validated for adults, and then extrapolated to five paediatric age 
groups: neonates/12 days, infants/18 months, children/2 years, children/6 years, and 
adolescents/12 years. Simulations were performed for fasted and fed states (different age-
appropriate meal types). The simulated plasma concentration-time profiles indicated delayed 
paracetamol absorption from HMC formulations in comparison to immediate-release 
formulations. Also, the simulations revealed that co-administration of food is not expected to 
affect paracetamol absorption following oral administration of HMC formulations, in contrast 
to immediate-release formulations whereas marked food effect was anticipated. 
According to the simulations results, HMC granules and tablets made of HMC granules can 
provide prolonged drug effect, irrespective of the presence of food, and consequently better 
compliance of paediatric patients. 
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Modelling penetration through the skin is a specific challenge. In the permeation analysis of 
dermal formulations, human skin is defined as a standard by regulatory agencies. However, 
there are artificial membranes which can replace human skin to some degree. Academicians 
and pharmaceutical firms are focusing on developing structured procedures and safe, 
effective alternatives to human skin in permeability studies. In my research work, I examined 
specific in vitro experiments to test semisolid preparations. In this study hydrogel and two 
forms of creams have been investigated as the most widely used dermal preparations. The 
parallel artificial membrane permeability assay (PAMPA) and Raman mapping methods were 
compared to the gold standard Franz cell process. The diffused amount of drug showed similar 
results for the different formulations. These findings are well aligned with the results of the 
Raman mapping. Our results indicate that any early screening experiments can be carried out 
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Personalized medicine is recently emerging trend, therefore pharmaceutical industry faces a 
new challenge on providing solid dosage forms, which as still the most favourable medicines, 
with tailorable properties. A novel approach may be the utilization of drug-polymer 
interactions in the development of solid delivery matrices. 
A line of chemically similar drugs with increasing acid strength were mixed various matrix 
forming agents and directly compressed with an instrumented IMA Kilian SP300 tablet press. 
Kawakita and Walker analysis were made to evaluate the composition’s compressibility. 
Compressibility studies showed an increment in the energy value needed for deformation, 
which may be due to particles attracted to each other causing chemical interactions. 
The presence of solid-state drug-polymer interactions based on the formation of H-bonds 
were confirmed by FT-IR spectroscopy.  
A custom-made device was applied to perform dissolution tests to obtain information on the 
effect of interactions on the drug liberation kinetics. The results of dissolution tests proved 
that strength of interactions have increased due to formation of polyelectrolyte complexes 
which exerted considerable influence on both the quantity of liberated drug and the speed of 
drug liberation.  
According to the findings it may be concluded that inclusion of the physico-chemical 
properties of raw materials and careful evaluation of their potential interactions during the 
development phase of the drug delivery systems may open new ways to provide medicines 
with tailored properties. 
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Betulinic acid (BA) is a pentaciclic triterpene, exhibiting strong cytotoxic activity but low water 
solubility, which affects its bioavailability and biological activity. Extensive studies have been 
carried out for increasing the solubility and bioavailability of BA, one option being BA-
bioconjugates with gold nanoparticles (GNP). The synthesis of BA GNP bioconjugates was 
achieved by using cysteamine as a linker between the organic molecule and the metallic 
surface of GNP. BA’s carboxylic group was condensed to the amine group of cysteamine using 
DCC and DMAP in dichlormethane. The completion of the reaction was monitored by means 
of TLC. The obtained BA amide was purified by flash column chromatography. FT-IR and LC-
MS analysis confirmed the identity of the synthesized compound. Synthesis of GNPs was 
conducted accordingto a previously published procedure. The synthesis is achieved by 
reducing chloroauric acid (HAuCl4) withtrisodium citrate dihydrate (C6H5O7Na3∙2H2O) using a 
HAuCl4:C6H5O7Na3molar ratio of 1:3.5. The obtained clear ruby-redsolution was cooled at 
room temperature. Purificationwas accomplished by repeated steps involving 
centrifugationfollowed by washing with deionized water. The finalproduct was lyophilized and 
resuspended in methanol. A methanolic solution of BA-cysteamine amide was added drop 
wise to the methanolic suspension of GNPs, under continuous stirring for 24h, allowing the 
thiol group to attach to the metallic surface. After the completion of the reaction, methanol 
was slowly evaporated under reduced pressure and the obtained formulation was washed 
with deionized water, centrifuged and lyophilized. The obtained product was refrigerated. This 
current nanoformulation will be further investigated for its proposed anticancer activity.  
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Matrix tablets represent the most favourable form of the modified release drug delivery 
systems intended for oral administration, due to their cost-effectiveness and easy 
preparation. The formulation of matrix systems using mucoadhesive polymers (such as guar 
gum) leads not only to prolonged drug release, but also enables targeting and localizing them 
to a specific site in the gastrointestinal tract (e.g., colon) [1]. It is well known that the 
conditions for drug vary along the gastrointestinal tract (GIT). Consequently, the dissolution 
characteristics of these systems should allow for the drug to be released in a controlled 
manner over the different segments of the GIT. This highlights the importance of dissolution 
testing in media, which simulate the changes in the composition of GIT fluids (i.e., biorelevant 
media). Therefore, the main aim of this study was to investigate the effect of two 
mucoadhesive polymers and their combinations without any additional excipients (e.g., fillers, 
lubricants) on the dissolution profile of a model drug, theophylline. To simulate the passage 
of the systems through the GIT, three biorelevant media simulating the fasted state gastric, 
intestinal, and colon fluids (FaSSGF, FaSSIF, and FaSSCoF) of pH 1.6, 6.5, and 7.8, respectively, 
were used. The results demonstrated that the formulations could sustain the release of the 
drug for 24h in all media and the influence of pH differences of media on the drug release 
patterns were negligible. 
 
Acknowledgments: This study was supported by Project No. 70119/2019 of Grant Agency of 
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Recently, research has been focused on developing dermal local anesthetic treatment to 
decrease pain before a surgical intervention. This treatment is non-invasive and painless, 
therefore provides an attractive alternative to injection. Lidocaine hydrochloride (LID-HCl) is 
a commonly used drug in local anesthesia, but its effective time is short. Film-forming system 
(FFS) is an innovative drug delivery system, which forms a film after application, dries fast, and 
has good mechanical properties. These advantages make FFSs a promising choice in local 
anesthesia.  
The aim of my research work was to develop LID-HCl containing semisolid in situ FFSs using 
the Quality by Design (QbD) approach. The FFSs were developed from the silicone containing 
blank formulations, which were used in my previous research. They were investigated 
regarding the effect of LID-HCl on the film-forming properties and the skin permeation of the 
active ingredients. The QbD approach was used to ensure the quality-based development.  
During the research, initial risk assessment identified four high-risk critical quality attributes 
(CQAs): in vitro drug release, in vitro drug permeation, drying properties and mechanical 
properties, and three medium-risk CQAs: pH, viscosity, and film appearance. Furthermore, 
four high-risk critical material attributes (CMAs) were also considered during the formulation: 
permeation enhancing excipients, drying excipients, film-forming excipients, and emollients. 
These parameters were investigated during the work.  
Results show that LID-HCl has great impact on FFSs. The silicone content can improve the 
applicability of formulations and has a favorable effect on the permeation rate of LID-HCl. 
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Deposition studies on a systematically modified paediatric 
throat geometry 
Laura Falkenstein, Joerg Breitkreutz, Peter Kleinebudde 
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Düsseldorf, Duesseldorf, Germany 
 
Inhaling drugs seems to be an upcoming therapy option in many indications due to various 
advantages: less active pharmaceutical ingredient (API) is needed to achieve an effective 
dosage, a rapid onset of action and a therapy opportunity in case of inability to swallow. 
Because of age- dependent differences in upper airway geometries and breathing patterns it 
is difficult to predict the pulmonal deposition of API´s, especially in paediatric inhalation 
therapy. Assessing the pulmonal deposition is especially important in evaluating the efficacy 
of therapy and dosage finding. 
A few geometry models, which should improve the knowledge about the particle deposition, 
were introduced in literature which try to reflect the tracheobronchial region of children. 
However, none depicts the age-specific differences. 
Therefore, a known paediatric throat geometry was modified in different dimensions and 
realized via 3D-printing. Constrictions were built in systematically to investigate the particle 
deposition in the upper airways and to determine the amount of API which is able to reach 
the lungs. Aerodynamic assessment was performed with the Next Generation Impactor (NGI) 
according to the Ph. EUR 2.9.18 using the example of “Cyclocaps® Salbutamol sulphate 
200µg”and the modified throat geometries instead of the sample induction port (SIP). 
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Nowadays, the interest in the development of novel dermal delivery systems for efficient 
therapy of skin weaken by various environmental stressors is steadily growing. Namely, 
environmental agents activate cutaneous inflammatory pathways and induce oxidative stress 
particularly by lowering the levels of antioxidants, which is associated with various skin 
diseases. Supporting the endogenous skin antioxidant system has been thus recognized as 
extremely beneficial [1, 2].  
The purpose of the present work was to evaluate and compare different lipid based delivery 
systems for dermal administration of vitamins with antioxidant properties in terms of their 
stability and antioxidant activity. Dermally applicable lyotropic liquid crystals and 
microemulsions, all composed of the same ingredients but with different microstructure, were 
selected as carrier systems for simultaneous delivery of hydrophilic vitamin C and lipophilic 
vitamin E. The influence of selected delivery systems on the stability of incorporated 
antioxidants was assessed by HPLC method while their antioxidant capacity was investigated 
using DPPH assay.  
Obtained results revealed differences in the stability among incorporated vitamins in 
correlation to the type of the delivery system, with lyotropic liquid crystals as most perspective 
formulation. Additionally, the study also demonstrated that the antioxidant efficacy of studied 
vitamins depends on their concentration and that the internal structure of the delivery system 
to some extent affects ability of incorporated vitamins to neutralize radicals.  
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The use of foams is becoming increasingly popular in the pharmaceutical and cosmetic fields. 
Foams are colloidal systems in which gas bubbles are dispersed in a solid or liquid dispersion 
medium. Pharmaceutical foams are usually applied topically, through dermal, vaginal, or 
rectal routes [1]. Foams have many beneficial properties over conventional carrier systems, 
which increases patient adherence, such as rapid and convenient application, even on 
extensive or hirsute, on sensitive and inflamed skin surfaces [2]. The aim of my work is to 
determine the investigation methods suitable for studying the physicochemical, structural 
properties and stability of dermally applied foams. 
In the course of my research, the foam formulas were developed on the basis of literature and 
then I studied their characteristics by macroscopic, microscopic, rheological and structure 
analysis methods. Through microscopic examination the structure and bubble size of the 
foams were determined. The structure of foams was also studied by oscillometric rheology, 
during the measurements I proved what deformations would occur in the structure of the 
foam due to deforming forces. Furthermore, using Texture analyzer, I investigated the 
spreadability of the foams to model the dermal application.  
Based on the results, it can be said that the selected instruments and the applied test methods 
are suitable for studying the properties and stability of foams. 
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Increasing attention has been raised towards biopharmaceutical drugs in the last two decades 
as a result of known advantages compared to the small drug entities [1]. The design space of 
lysozyme loaded pellet production was optimized in the frame of raw material attributes by 
applying a special granulation chamber (Opulus®, Hungary) to take the encountered thermal 
shocks generated by the mechanical stress during the production steps into account as 
prescribed by [2]. The aim of the present work is to optimize the consecutive coating process 
in a manner to preserve pellet quality. The coating processes were performed based on 23 full 
factorial design with a center point. The effects of atomizing pressure, drying air temperature 
and drying air pressure were set as investigated factors, and pellet properties were set as 
optimization parameters. It was found that pellets demonstrated good thermal stability at the 
applied coating temperatures. Atomizing pressure was found as main factor affecting enzyme 
activity, moisture content, hardness, and release behaviour. Also, it is recommended to 
increase spheronization time to improve sphericity and then film homogeneity. In addition, 
increasing coating thickness is crucial to prevent premature drug release. Based on the 
biological activity and release pattern, the optimization of the coating process was successful, 
and the delivery system may be utilized for treating GI infections or as adjuvant regimen for 
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Stigmasterol (STIG) among the most plentiful plant sterols has been demonstrated to possess 
a wide range of biological activities. However, the therapeutic use and efficacy of this plant 
sterol are limited due to its poorly water-soluble characteristics. To overcome these 
challenges, the present study was undertaken to formulate novel amphiphilic electrospun 
nanofibers (NFs) loaded with STIG, phosphatidylcholine and polyvinylpyrrolidone. The 
chemical structure of STIG, surface morphology, physical solid state, and drug–polymer 
interactions of NFs were characterized using nuclear magnetic resonance (NMR) 
spectroscopy, scanning electron microscopy (SEM), Fourier transform infrared (FTIR) 
spectroscopy, X-ray powder diffraction (XRPD), and differential scanning calorimetry (DSC), 
respectively. The drug release of NFs was investigated in vitro using an in-house dialysis-based 
dissolution method. The STIG-loaded NFs presented a nano-scale size of 297 ± 56 nm. The 
liposomes with a diameter of 436 ± 64 nm were spontaneously formed as the NFs were 
exposed to water. The entrapment efficiency of liposomes was 57%. In conclusion, the present 
amphiphilic NFs loaded with STIG enable a promising alternative approach for drug delivery 
of the present poorly water-soluble plant sterol. 
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This study aimed to develop liposomes and solid lipid nanoparticles (SLNs) encapsulated with 
n-propylgallate (PG) as potential platforms for nose-to-brain delivery of anticancer drugs. The 
lipid formulation loaded with PG was not studied previously through this administration route, 
therefore its investigation and optimization is promising. The liposomes, solid lipid 
nanoparticles were developed by direct pouring method and solvent injection method 
respectively following the Quality by Design approach. The risk assessment strategy was used 
to screen and rank the critical quality attributes that can affect the final PG loaded 
nanoparticles. The 3-factor Box Behnken Design and Response surface Quadratic models was 
used to optimize the formulations of liposomes and solid lipid nanoparticles respectively. The 
lipid nano-formulation showed good compatibility according to results of XRPD, FTIR and DSC. 
The PG-SLNs showed encapsulation efficiency of 84±0.5%, particle size of 103±46.04 nm with 
polydispersity index of 0.16±0.001 and zeta potential of -36±4.78 mV. The PG-liposomes 
showed 90 ± 3.6% encapsulation efficiency, 167.9 ± 3.5 nm average hydrodynamic diameter, 
0.129 ± 0.002 PDI and -33.9 ± 4.5 zeta potential. In vitro drug release and permeation studies 
of both formulation in simulated nasal conditions were performed. Both lipid 
nanoformulations resulted in enhanced nasal permeability and sustained release of 
nanoformulation compared to the PG solution. The optimized formulations showed high 
potential to be used to target the brain via intranasal route. 
 
Acknowledgements: This work was supported by the Ministry of Human Capacities, Hungary 
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Nanofibers provide unique opportunities for drug delivery and tissue engineering. Despite 
many advantages of nanofibers, they are not yet in clinical use, mainly due to insufficient data 
about safety. Exploring nanofiber safety starts with in vitro testing, but unlike nanoparticles 
that have a clearly defined assay cascade by European Nanomedicine Characterisation 
Laboratory, tests need to be established or modified to account for additional considerations. 
We identified three main areas of challenges in in vitro testing of nanofibers namely pre-
processing, cell culture experiment and evaluating the results. Challenges in pre-processing 
start with preparation of nanofibers (aseptic work) with constant nanofiber mat thickness, 
and clean nanofiber sample edge. MTS proliferation assay has proven to be sensitive to 
nanofiber sample orientation, size, and nanofiber collector material. Challenges in evaluating 
MTS proliferation assay results remain due to cell infiltration in nanofiber mat, formazan dye 
absorption into nanofibers and absorbance determination. Experimental nanofiber mats were 
made with an electrospinning device collected on glass or aluminium base. A model in vitro 
test was MTS proliferation assay performed in 96 and 48 well microtiter plates with primary 
blood derived cells. Experiments were designed using “Design of Experiments” approach to 
evaluate the influence of individual assay configurations. Most of the challenges can be 
overcome in the pre-processing phase with optimised nanofiber mat thickness, accurate 
nanofiber cutting or limiting the assay area with a microtiter insert glued to the nanofiber mat. 
Formazan dye absorption can be determined with additional experiments to measure the 
absorption capacity of nanofibers. With optimisation of described experimental parameters 
we expect more accurate in vitro results. 
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Gene therapy emerged as an alternative to small drugs and proteins in the treatment of a 
large variety of diseases. However, the administration of nucleic acids still remains a challenge 
due to the biological barriers that need to be overcome before reaching the target cells. 
Indeed, polynucleotides are very sensitive to degradation and cannot cross cell membranes. 
To overcome these obstacles, nucleic acids are often included in viral, lipid or polymeric 
particles. Polymeric gene nanocarriers offer chemical flexibility and good protection for the 
therapeutic genes, but the materials used still need to the optimized to achieve improved 
efficiency in the gene delivery process. 
Considering this background, the objective of this work has been the development of new 
prototypes of polymeric nanoparticles for their use in gene therapy and to test their potential 
for the treatment of glioblastoma. For this, a variety of synthetic cationic polymers have been 
combined with plasmid DNA or with both plasmid and an endosomolytic polymer. The 
nanoparticles were characterized for their physicochemical properties, for their toxicity and 
transfection efficiency in cell cultures. The polymer having primary amines and hydrophobic 
side groups, combined with the endosomolytic polymer provided some of the best results 
regarding their transfection/toxicity ratio. This advanced prototype was used with a 
therapeutic plasmid encoding Bone Morphogenic Protein-4 as a potential treatment against 
glioblastoma. These therapeutic nanoparticles showed the capacity to suppress glioblastoma 
growth in a murine xenograft model when combined with Temozolomide, due to the 
synergistic effect between those two treatments administered together. 
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Milk-based formulations are promising approaches for drug delivery. Its nutritional function, 
considerable effect on the drug solubility and taste masking capacity, recommended milk as 
potential excipient. This work aimed to investigate the properties of milk for paediatric oral 
lyophilisates (OLs) preparation and its influence on the quality profile.  
A D-Optimal screening experimental design, with three independent variables: suspended 
active pharmaceutical ingredient (API) dose - loratadine, alveolae volume and the type of milk 
(1.5% and 3.5%) was generated and led to 16 formulations. The OLs were characterized for 
the disintegration time, texture and dissolution profile and particle size analysis upon 
reconstitution.  
The independent variables included into the experimental design had significant influences on 
the output and gave robust models for all responses. A good OL excipient should allow fast 
disintegration and good mechanical profile. Disintegration was facilitated by high API content, 
small alveolae and low fat milk, correlated to weaker mechanical structures. However, 
appropriate mechanical profiles with hardness over 600g were obtained for most 
formulations, especially for the ones containing low doses of API. Dissolution was favoured by 
high API content and low fat milk. Low particle sizes upon reconstitution could improve both 
palatability and API dissolution and were granted by high alveolae volumes and low lipid 
content. 
These results showed the feasibility of milk structures that meet OLs’ quality criteria, indicated 
a rational way to choose the type of milk and highlighted the effects of the API dose and 
product volume. 
Acknowledgements: This work was supported by a grant of the Romanian Ministry of 
Education and Research, CNCS - UEFISCDI, project number PN-III-P1-1.1-PD-2019-0795, within 
PNCDI III. 
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Non-steroidal anti-inflammatory agents, such as meloxicam (MEL), play a key role in the 
treatment of the Alzheimer’s Disease-associated neuroinflammation which leads to the loss 
of physiological functions. 
Our aim was to develop MEL-loaded Soluplus® polymeric micelles and to test the application 
of them for the auspicious nose-to-brain drug delivery pathway in order to be a potential 
therapeutical nano system in the therapy of neuroinflammation. 
To decrease the need of in vivo testing, various in vitro methods were used to investigate 
dissolution and permeability throughout this pathway. In vitro drug release at nasal conditions 
were tested in simulated nasal electrolyte solution. Cellular uptake and viability were 
investigated on human RPMI 2650 nasal epithelial cells. Using rapid equilibrium dialysis and 
parallel artificial membrane permeability assay, passive diffusion was investigated as the 
determining transport through penetration of the blood-brain-barrier. IVIVC was calculated 
based on these results. 
Based on the in vitro results, we found that the nanoparticles tend to follow this pathway 
more favourably compared to the initial MEL. The formulation is viable to nasal epithelial cells 
with high trans-epithelial transport capacity. Rapid release kinetics paired with high flux and 
permeability values were determined at axonal conditions. A significantly higher simulated 
cerebral concentration of MEL was detected in the case of the nanoparticles. 
In conclusion, it can be claimed that by encapsulating MEL into a polymeric micelle, 
prosperous pharmacokinetics can be achieved which can be used in the treatment of 
neuroinflammation. 
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Oral delivery of biopharmaceuticals has been representing an extensively active area of 
research during last decades. Part of this increasing interest comes from the superiority of this 
route over the parenteral one in terms of patients’ convenience and compliance. However, 
biopharmaceuticals are delegate materials and are liable to degradation and inactivation 
during manufacturing and transit in the GIT after administration. Several studies utilised a 
variety of nanocarriers systems to deliver those macromolecules through this route. Among 
them, hybrid nanoparticles constitute a promising approach to achieve this mission. Based on 
the physicochemical properties of the loaded drug and the required features of a platform, a 
variety of one-step and two-step methods have been employed to fabricate these hybrid 
nanocarriers. Printing technology, recently introduced to the pharmaceutical field, seems to 
have the potentiality to prepare such systems. 
This project aims the investigation of the emerging area of additive manufacturing, namely 
syringe extrusion technique and inkjet printing, for the construction of orally delivered 
peptide-loaded hybrid nanocarriers. In this study, the principles of Quality by Design and 
Design of Experiments will be exploited to investigate the process parameters and material 
attributes that affect the characteristics and the performance of the printed hybrid 
nanocarriers. The physical characteristics of the nanocarriers and the biological activity of the 
peptide will be examined. After that, the design space for the optimized response will be 
determined and verified. 
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Fused deposition modelling (FDM) is an additive manufacturing technology that utilizes a 3D 
design to create an object by depositing molten materials on a platform in a layer-by-layer 
manner. The feedstock of the FDM printers is called filament and it is created using a hot melt 
extrusion process (HME) [1]. Although, FDM coupled with HME process has been intensively 
researched and developed in recent years, printability and various parameters affecting 
printability is still an unknown field. 
The aim of this study was to evaluate influence of mechanical properties of filaments on 
printability through three-point bend test. The parameters that were observed were 
maximum force (N), maximum stress (N/mm2) and maximum displacement (mm).  
After integrating obtained data for all 90 samples in a data mining environment software 
RapidMiner Studio version 9.7.0 (Boston, USA) and after analysing it via visual tools (Decision 
tree model) the correlation between maximum displacement, maximum force and printability 
was found. It was observed that filaments with the maximum displacement greater than 1.09 
mm had a tendency to be printable, while filaments with the maximum displacement bellow 
this value were not printable. Additionally, if maximum force was lower than 9.61 N, filaments 
were printable. Otherwise, if maximum force was greater than 9.61 N, even with maximum 
displacement greater than 1.09 mm, printing was impossible. The method achieved an overall 
accuracy of 84.85%.  
This study showed that the three-point bend test can be successfully used as an initial 
predictor of printing abilities of obtained filaments. 
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Personalized medicine is about to become the most efficient and sustainable way of practice 
both in prevention and treatment. A key enabling technology of personalized medicine is 3D 
printing, or Additive Manufacturing (AM) as more commonly known, nowadays. The 
conceptually simple, but radically new approach of AM roots in building objects additively, i.e. 
layer-upon-layer from a digital blueprint. The material of the object could either be plastic, 
metallic or even certain human tissue, depending on the AM technology used. 
The 3D Printing Center of the University of Szeged (3DC) has been recently launched to merge 
and increase the knowledge of relevant research teams within the University and open up 
opportunities to those who are new to resolving the potential of AM.  
The main emphasis of the 3DC is on life science and is equipped with high-end imaging and 3D 
printing instrumentation. Our metal printer is capable to print in an extensive portfolio of high-
tech materials but can also be run with medical-grade titanium and stainless-steel alloys, 
appropriate for implants and medical instruments. We have two professional, high-resolution 
resin 3D printers capable to print even biocompatible materials. The 3DC is addressing 
bioprinting with a mechanical and a pneumatic printer, while teaching is assisted by several 
of our desktop printers of SLA and FDM technology. Last, but not least a metrological 3D 
scanner is also available, along with several other auxiliary instruments, such as a 3D optical 
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Pulmonary drug delivery provides rapid onset of action, large surface area for absorption and 
limited drug degradation. With the development of innovative dry powder inhalers, we could 
improve the therapeutic effect. The non-steroidal anti-inflammatory meloxicam was the 
active ingredient, which could be useful for the treatment of lung cancer, cystic fibrosis and 
chronic obstructive pulmonary disease. 
Our aim was to produce dry powder inhalers containing nanonized meloxicam. We targeted 
different regions of the lung with micrometric particles prepared by Mini Spray-Dryer and 
nanometric samples produced by Nano Spray-Dryer.  
We used a two-step preparation method. The nanosuspension was prepared with wet milling, 
using meloxicam and polyvinyl alcohol. The powders were obtained with spray-drying of the 
nanosuspension and using leucine. We measured the following properties: particle size (laser 
diffraction, DLS), morphology (SEM), true density, structure (XRPD), thermoanalytical 
properties (DSC), in vitro dissolution, in vitro absorption, in vitro lung deposition (Andersen 
Cascade Impactor). 
We worked out a powder preparation method, using wet milling and spray drying. We 
managed to nanonize the active ingredient and prepare 3-4 µm particles by Mini Spray-Dryer 
and 500-800 nm particles by Nano Spray-Dryer. The particles were spherical with low density. 
Thanks to the improved surface area and amorphization, released and absorbed amount of 
meloxicam increased. The in vitro aerodynamic measurements proved that with the 
microsized particles we targeted the bronchioles and with the nanosized we reached the 
alveoli. 
The samples are suitable for pulmonary delivery; therefore, our products could treat different 
respiratory diseases in the future. 
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Premature removal of nanocarriers in mucosal tissues, their enzymatic degradation and 
elimination by intestinal immune cells constitute current limitations on nanocarrier-mediated 
oral delivery of biopharmaceuticals [1]. Herein we present a strategy to overcome these 
limitations based on a biomimetic multi-stage delivery platform, using natural pollen-derived 
biomaterials [2]. 
For this purpose, we produced hollow pollen microcapsules (HPMs) with the same external 
structure as intact pollen grain, but free of internal compounds and potential contaminants, 
and we loaded them with non-biodegradable model nanoparticles of different sizes and 
surface charges. Association efficacy was studied by different techniques and lack of 
allergenicity was analyzed in the presence of immature dendritic cells and macrophages. 
Mucointeraction was also evaluated in vivo upon oral gavage to healthy rats. Results showed 
that 200 nm non-biodegradable model nanoparticles reached an optimal internal loading 
(around 85%) and a controlled release profile during the initial 8 h followed by a continuous 
release up to 120 h in simulated intestinal fluid. Further, this platform did not present 
allergenic effects, while their specific 3D surface morphology enabled an efficient and 
prolonged interaction with the intestinal mucosa upon oral administration, preserving 
intestinal tissue integrity. These characteristics places this pollen microcapsules as interesting 
multistep delivery platform candidates for the oral delivery of biopharmaceuticals.  
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In order to meet the requirements of the constantly growing market for high quality medicinal 
plant products, the extraction and separation techniques that provide these products are in a 
state of constant development and improvement. Traditionally, the products of aromatic 
medicinal plants have been obtained by classical extraction methods such as hydrodistillation 
and Soxhlet, which are used to separate the fat and volatile fractions of these plants. These 
traditional methods, although well-known and documented, have a number of negative 
characteristics that can affect product quality such as toxic solvents residue, non-selective 
extraction and high energy consumption due to long extraction time as well as thermal 
degradation of high-value products. In order to neutralize the problems of traditional 
extraction techniques, new extraction methods have been introduced, such as supercritical 
carbon dioxide extraction and subcritical water extraction, which are aligned with strict 
requirements of the market and green chemistry. In this study, aromatic medicinal plants were 
extracted using supercritical carbon dioxide extraction and subcritical water extraction to 
demonstrate the advantage of using these modern and green extraction methods. 
Considering that obtaining the product with highest content of bioactive components was the 
primary goal, the advantages and disadvantages of the applied process were classified based 
on the chemical characterization of the extracts. 
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Meloxicam (MEL) could relieve acute pain by absorbing through a highly vascularized 
alternative route: the nasal mucosa. However, there is an issue that requires a solution: the 
poor water-solubility of MEL. Chitosan can help to overcome this problem and because it is 
mucoadhesive, capable of opening the epithelial tight junctions and can achieve controlled 
drug delivery, there is a growing interest in it as a biocompatible matrix for nasal drug delivery 
in pharmaceutical developments [1]. The aims of this work were to prepare non-cross-linked 
and cross-linked drug-free and MEL-containing chitosan-based microparticles by spray drying 
while optimizing the process parameters and the composition of the formulation. The effect 
of inlet air temperature and pump rate on the particle size distribution and morphology of 
drug-free chitosan particles was investigated to determine the optimal parameters. After that, 
the micrometric properties, structural characterization and in vitro drug release of MEL-
containing samples were studied. Sodium tripolyphosphate (TPP) was used in different 
amounts as the cross-linking agent. Micronized chitosan particles were successfully prepared 
regardless of the process parameters and the concentration of TPP. Nearly spherical habit 
could be observed in the case of drug-containing samples. The highest amount of molecularly 
dispersed MEL dissolved from the non-cross-linked formulation, controlled drug release was 
observed. Based on the mentioned results, spray-dried chitosan microparticles containing 
MEL may offer an opportunity to reduce acute pain or enhance analgesia through the nasal 
route. 
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Pentacyclic triterpenes are natural occurring compounds with well described pharmacotherapeutic 
potential but have some pharmacodynamic drawbacks such as low bioavailability [1]. To address this 
inconvenience, previous studies have attempted various formulations in order to increase their 
bioavailability and antitumor activity [2,3]. The current study proposes the structural design of a series 
of new gold nanoparticle (GNP) based bioconjugates in which each component can exert a synergic 
antiproliferative effect. 
In our current work, based on their antiproliferative activity against malignant melanoma, ursolic acid, 
oleanolic acid and betulinic acid were chosen to be formulated as GNP bioconjugates. In order to bind 
to the GNP surface, the use of linker molecules is required. For the conceptualization of chemically 
suitable linkers that are also potentially active in melanoma, we choose the 3-mercapto-4-amino-1,2,4-
triazole ring as a starting point template. In this regard, a virtual compound library was constructed (3-
mercapto-4-amino-5-R-1,2,4-triazole derivatives) for the purpose of obtaining a selection of 
potentially active molecules, using molecular docking based virtual screening. The target proteins 
chosen are key nodes in melanoma active signalling pathways. The 3D structures of the targets were 
obtained from the RCSB database: EGFR (1XKK), MEK1 (3EQG), AKT1 (4GV1), mTOR (4JT5) and PI3Kα 
(6GVF). After docking the compound library in the mentioned targets, using PyRx, based on the 
obtained docking scores and binding site pose analysis, five compounds were retained as possible 
candidates with theoretical antiproliferative potential: 4-amino-5-(4-ethoxyphenyl)-1,2,4-triazole-3-
thiol, 2-(4-amino-5-sulfanyl-1,2,4-triazol-3-yl)phenol, 4-amino-5-(4-nitrophenyl)-1,2,4-triazole-3-thiol, 
4-amino-5-(2-naphthyl)-1,2,4-triazole-3-thiol, 4-amino-5-(4-quinolyl)-1,2,4-triazole-3-thiol. These 
molecules will be used as linkers in the synthesis of future pentacyclic triterpene-GNP bioconjugates. 
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Transfer of twin-screw granulation process using a shear 
stress description of screw configuration 
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Factors like liquid-to-solid ratio (L/S), screw configuration and barrel fill level have crucial impact on 
the extent of granule formation [1]. Strategies that allow successful process transfers onto twin-screw 
granulators of different barrel diameters, without necessity of numerous experiments, are rare and 
still challenging [2,3]. 
Aim of this study was to transfer a TSG process using a newly developed equation that numerically 
describes the screw configuration as shear stress (τ) 
 
Two granulators of different barrel diameters (Pharma: 16 mm, QbCon: 25 mm) were used. The 
granule size distributions (GSD) of the original granules were compared only in the first place (Fig. 1). 
The GSD curves were comparable to each other with regard to their characteristics. Deviations were 
noticed above approx. 1000 µm only, resulting in higher x90 values for the granules produced on the 
QbCon. In a second step and to draw a final conclusion, process transfers were performed, where the 
original and turbo-sieved granules as well as tablets were characterized according to the European 
Pharmacopoeia. Very similar characteristics could be revealed. A successful transfer can be assumed. 
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Protamine-based nanoparticles: an attractive gene 
delivery system for 2D and 3D glioblastoma models 
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Glioblastoma multiforme is one of the most aggressive brain tumors. Its treatment combines 
surgical resection, chemotherapy, and radiotherapy, at expense of severe side-effects. Gene 
therapy holds great promise due its capacity to target specific pathways within glioblastoma 
cells by the introduction of exogenous tumor suppressor sequences, which are rendered 
therapeutically effective by using nanocarriers. Protamine:Dextran nanoparticles have 
become an attractive gene delivery system due to their intrinsic ability to encapsulate and 
protect nucleic acids, and the delivery efficacy. These NPs present spherical morphology, size 
below 150 nm and positive surface charge. They present long-term stability for one month 
under storage conditions (4ºC) and short-term stability for 4h when diluted in simulated 
physiological media (37ºC, pH=7.4). The association of different nucleic acids to these NPs was 
studied by agarose gel electrophoresis, showing high encapsulation (≥90%). In vitro cell-
viability studies were optimized using U87MG cells and spheroids models, then followed by 
assessment using primary patient-derived glioblastoma cells. Toxicity was studied with 
proliferation and cell-death assays indicating low/non-toxicity for this nanosystem. Particle 
uptake in both glioblastoma models was tested with fluorescently labelled-nanosystem using 
confocal microscopy and quantified by Flow Cytometry. The studies revealed an uptake 
efficiency of 99%. The transfection of different doses of pDNA was carried out with a model 
plasmid encoding the Enhanced Green Fluorescent and Luciferase Proteins. These studies 
showed the capacity of NPs to efficiently transfect U87MG cells and spheroids at doses greater 
than 1 ug/well. This new formulation could be considered as a promising gene-nanocarrier for 
glioblastoma treatment. 
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In the first step of the study, the production process and product quality of TNT composites 
with atenolol and hydrochlorothiazide [1] were successfully optimized. Nevertheless, to use 
titanate nanotubes (TNTs) as drug delivery systems, the tailoring of their surface 
characteristics and hydrophilicity may be essential. Trichlorooctylsilane (TCOS), 
trichloroocatdecylsilane (TCOdS) and Mg stearate (MgSt) were used as functionalizing agents 
to increase their permeability through the GIT.  
In this step, the functionalized TNTs were characterized by using a vario EL cube elemental 
analyzer to determine the H, C, N, and S contents and an optical contact angle tester to 
investigate the surface free energy. Furthermore, Caco-2 cell lines were utilized to test the 
cytotoxicity of the functionalized TNTs with MTT assay as well as permeability, where the 
concentration of the permeated amount was determined with an X-ray fluorescent analyzer. 
According to the OCA results, for silane-based materials there was no significant difference in 
the polarity of TNTs when using the different molecular sized TCOS and TCOdS. There was a 
proportional linear relationship between the concentration of the agent and the polarity of 
TNTs, and the maximum hydrophobicity was achieved by using 100 µL of both, therefore, the 
functionalization reagent may be selected on an economical basis. In contrast, the surface 
characteristics of TNTs showed a sigmoidal relation to MgSt, which enables the use of less St 
and more uploaded drug molecules. Furthermore, functionalization with MgSt is a water-
based green method, and altogether seems to be a better choice to achieve the targeted aims. 
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